Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: An European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study

H. Gelderblom, J. Y. Blay, B. M. Seddon, M. Leahy, I. Ray-Coquard, S. Sleijfer, J. M. Kerst, P. Rutkowski, S. Bauer, M. Ouali, S. Marreaud, R. J.H.M. Van Der Straaten, H. J. Guchelaar, S. D. Weitman, P. C.W. Hogendoorn, P. Hohenberger

Research output: Contribution to journalArticlepeer-review

19 Scopus citations

Abstract

Aim Brostallicin is a DNA minor groove binder that has shown activity in patients with soft tissue sarcoma (STS) failing first-line therapy. The present study assessed the safety and efficacy of first-line brostallicin in patients with advanced or metastatic STS > 60 years or not fit enough to receive combination chemotherapy. A prospective explorative pharmacogenetic analysis was undertaken in parallel. Methods Patients were randomised in a 2:1 ratio between IV brostallicin 10 mg/m2 and doxorubicin 75 mg/m2 once every 3 weeks for a maximum of six cycles. Disease stabilisation at 26 weeks (primary end-point) was considered a 'success'. Further testing of brostallicin was warranted if ≥35 'successes' were observed in the first 72 eligible patients treated with brostallicin. In addition, patients were genotyped for glutathione S transferase (GST) polymorphisms. Results One hundred and eighteen patients were included (79 brostallicin and 39 doxorubicin). Brostallicin was well tolerated in comparison to doxorubicin with less grade 3-4 neutropenia (67% versus 95%), grade 2-3 systolic dysfunction (0% versus 11%), alopecia (17% versus 61%) and grade 2-3 mucositis (0% versus 18%). For brostallicin versus doxorubicin, 'successes' were observed in 5/77 versus 10/36, progression free survival at 1 year was 6.5% versus 15.6%, objective response rate was 3.9% versus 22.2% and overall survival at 1 year was 50.5% versus 57.9%, respectively. Only GSTA1 genotype was significantly associated with success rate of doxorubicin treatment. Conclusion Brostallicin cannot be recommended at this dose and schedule in this patient population as first-line therapy. GSTA1 genotype may be predictive for doxorubicin efficacy but warrants further study.

Original languageEnglish (US)
Pages (from-to)388-396
Number of pages9
JournalEuropean Journal of Cancer
Volume50
Issue number2
DOIs
StatePublished - Jan 2014

Keywords

  • Brostallicin
  • Doxorubicin
  • GST
  • Randomised phase II study
  • Soft tissue sarcoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: An European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study'. Together they form a unique fingerprint.

Cite this